38.64
price down icon0.49%   -0.19
after-market Dopo l'orario di chiusura: 38.55 -0.09 -0.23%
loading
Precedente Chiudi:
$38.83
Aprire:
$38.6
Volume 24 ore:
744.27K
Relative Volume:
0.69
Capitalizzazione di mercato:
$2.98B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-14.10
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
+0.10%
1M Prestazione:
+16.53%
6M Prestazione:
+7.27%
1 anno Prestazione:
-4.71%
Intervallo 1D:
Value
$38.12
$38.92
Intervallo di 1 settimana:
Value
$38.00
$39.84
Portata 52W:
Value
$26.74
$46.00

Xenon Pharmaceuticals Inc Stock (XENE) Company Profile

Name
Nome
Xenon Pharmaceuticals Inc
Name
Telefono
(604) 484-3300
Name
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Name
Dipendente
327
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
XENE's Discussions on Twitter

Confronta XENE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
XENE
Xenon Pharmaceuticals Inc
38.64 3.03B 13.17M -199.06M -156.53M -2.74
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.93 102.81B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
453.54 58.59B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.22 61.25B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
733.66 43.23B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.73 36.53B 3.81B -644.79M -669.77M -6.24

Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-07 Iniziato Chardan Capital Markets Buy
2025-02-11 Iniziato Deutsche Bank Buy
2024-10-10 Ripresa Raymond James Outperform
2024-10-01 Iniziato H.C. Wainwright Buy
2024-01-04 Iniziato Citigroup Buy
2023-12-08 Iniziato Robert W. Baird Outperform
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-04-25 Iniziato Cantor Fitzgerald Overweight
2022-12-14 Iniziato Goldman Buy
2022-12-12 Iniziato Cowen Outperform
2022-11-28 Iniziato Wells Fargo Overweight
2022-10-19 Iniziato Raymond James Outperform
2022-08-29 Iniziato BofA Securities Buy
2022-07-21 Iniziato JP Morgan Overweight
2021-10-28 Iniziato RBC Capital Mkts Outperform
2020-10-02 Iniziato SVB Leerink Outperform
2020-07-21 Iniziato Needham Buy
2020-06-01 Ripresa Jefferies Buy
2020-03-25 Iniziato Wedbush Outperform
2020-01-08 Iniziato William Blair Outperform
2019-09-20 Iniziato Guggenheim Buy
2018-08-08 Reiterato Stifel Buy
2017-03-13 Iniziato Jefferies Buy
2016-10-21 Iniziato Stifel Buy
2016-09-26 Iniziato Guggenheim Buy
2016-04-14 Reiterato Jefferies Buy
2015-10-30 Ripresa Jefferies Buy
2014-12-02 Iniziato Canaccord Genuity Buy
Mostra tutto

Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie

pulisher
Sep 03, 2025

How to build a custom watchlist for Xenon Pharmaceuticals Inc.Weekly Risk Report & High Conviction Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Xenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail

Sep 03, 2025
pulisher
Sep 03, 2025

Chart based analysis of Xenon Pharmaceuticals Inc. trendsJuly 2025 Update & Free Long-Term Investment Growth Plans - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Building trade automation scripts for Xenon Pharmaceuticals Inc.July 2025 Review & Consistent Profit Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Applying Elliott Wave Theory to Xenon Pharmaceuticals Inc.2025 Retail Activity & Stepwise Trade Signal Implementation - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Published on: 2025-09-03 01:33:36 - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Ranking Xenon Pharmaceuticals Inc. among high performing stocks via toolsJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Can swing trading help recover from Xenon Pharmaceuticals Inc. lossesIPO Watch & Fast Moving Market Watchlists - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Using AI based signals to follow Xenon Pharmaceuticals Inc.CPI Data & AI Powered Buy and Sell Recommendations - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Predicting Xenon Pharmaceuticals Inc. trend using moving averagesBuy Signal & Safe Capital Growth Plans - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Volume Recap: Can Xenon Pharmaceuticals Inc. navigate macro headwindsQuarterly Investment Review & Real-Time Chart Breakout Alerts - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Developing predictive dashboards with Xenon Pharmaceuticals Inc. dataPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

What is Xenon Pharmaceuticals Inc.’s book value per sharePortfolio Update Summary & Real-Time Volume Triggers - khodrobank.com

Sep 02, 2025
pulisher
Sep 02, 2025

Price momentum metrics for Xenon Pharmaceuticals Inc. explainedJuly 2025 Decliners & Weekly Top Gainers Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Xenon Pharmaceuticals shares fall 1.50% premarket after equity inducement grants to new employees. - AInvest

Sep 02, 2025
pulisher
Sep 02, 2025

RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN

Sep 02, 2025
pulisher
Sep 01, 2025

Understanding Xenon Pharmaceuticals Inc.’s price movementGap Up & Weekly High Conviction Ideas - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Is Xenon Pharmaceuticals Inc. reversing from oversold territory2025 Trading Recap & Intraday High Probability Alerts - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Using RSI to spot recovery in Xenon Pharmaceuticals Inc.2025 Trading Volume Trends & Community Verified Swing Trade Signals - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Xenon Pharmaceuticals Q2 Earnings Call Highlights Strong Progress and Promising Future - AInvest

Sep 01, 2025
pulisher
Sep 01, 2025

Xenon Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener

Sep 01, 2025
pulisher
Sep 01, 2025

What dividend growth rate does Xenon Pharmaceuticals Inc. offerWeekly Stock Summary & Weekly Watchlist for Hot Stocks - khodrobank.com

Sep 01, 2025
pulisher
Aug 31, 2025

Can machine learning forecast Xenon Pharmaceuticals Inc. recoveryJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

How to integrate Xenon Pharmaceuticals Inc. into portfolio analysis toolsTreasury Yields & Fast Exit and Entry Trade Guides - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Is Xenon Pharmaceuticals Inc. stock reversal real or fakeEarnings Beat & AI Enhanced Trading Alerts - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Key resistance and support levels for Xenon Pharmaceuticals Inc.2025 Price Action Summary & Fast Entry and Exit Trade Plans - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Using fundamentals and technicals on Xenon Pharmaceuticals Inc.Market Movement Recap & Safe Entry Zone Identification - Newser

Aug 31, 2025
pulisher
Aug 30, 2025

Xenon Pharmaceuticals Inc. stock volume spike explainedQuarterly Portfolio Summary & Daily Stock Trend Watchlist - Newser

Aug 30, 2025
pulisher
Aug 30, 2025

Xenon Pharmaceuticals Inc. Shows Early Signs of Technical Strength getLinesFromResByArray error: size == 0 - thegnnews.com

Aug 30, 2025
pulisher
Aug 30, 2025

Xenon Pharmaceuticals Inc. stock trendline breakdown2025 Short Interest & High Return Trade Guides - Newser

Aug 30, 2025
pulisher
Aug 30, 2025

Can volume confirm reversal in Xenon Pharmaceuticals Inc.Weekly Trade Review & Expert Verified Stock Movement Alerts - Newser

Aug 30, 2025
pulisher
Aug 30, 2025

Momentum divergence signals in Xenon Pharmaceuticals Inc. chart2025 Earnings Impact & Real-Time Volume Surge Alerts - Newser

Aug 30, 2025

Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Xenon Pharmaceuticals Inc Azioni (XENE) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
GANNON STEVEN
Director
May 14 '25
Option Exercise
12.57
5,144
64,660
7,144
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Option Exercise
17.76
22,468
399,032
53,770
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Option Exercise
17.76
16,315
289,754
46,468
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Option Exercise
17.76
16,217
288,014
47,519
MORTIMER IAN
PRESIDENT & CEO
Jan 24 '25
Sale
40.20
22,468
903,214
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 27 '25
Sale
40.50
16,315
660,806
31,302
MORTIMER IAN
PRESIDENT & CEO
Jan 23 '25
Sale
40.08
16,217
649,977
31,302
$85.44
price down icon 1.75%
$27.38
price up icon 1.11%
$23.80
price up icon 1.19%
$103.50
price up icon 3.07%
$142.53
price down icon 0.68%
biotechnology ONC
$318.73
price down icon 5.21%
Capitalizzazione:     |  Volume (24 ore):